Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
Globe Newswire•20/10/2026•07:00 ET
0
Key Highlights
- ➤OD-001 met its Week 12 primary endpoint, reducing modified Mayo score 2.4 points (p<0.001)
- ➤20 mg BID achieved 27% clinical remission, 61% response, and 49% symptomatic remission
- ➤OD-001 showed no serious adverse events, infections, discontinuations, or liver abnormalities
- ➤Odyssey plans Phase 2b monotherapy and Phase 2a combination trials, with 2027 topline results expected
Expert Statements
Gary D. Glick, Founder and Chief Executive Officer of Odyssey Therapeutics
“These new analyses provide compelling evidence of pharmacologic activity at 20 mg BID, including clinical efficacy in patients with severe endoscopic disease and improvements across markers of intestinal and systemic inflammation.”
Gary D. Glick, Founder and Chief Executive Officer of Odyssey Therapeutics
“Transcriptomic findings that align with clinical activity and are consistent with RIPK2 scaffolding inhibition reinforce the mechanistic rationale for this approach in inflammatory bowel disease, strengthen our confidence in the treatment activity of OD-001, and support its continued clinical development.”
Correlation between clinical efficacy and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously shown clinical proof of concept for OD-001
Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in inflammatory bowel disease
Get started
Create a free account to read the full story.